Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kreuter, A.K. Rossler, N. Kahn, K. Hornemann, T. Muley, F. Herth (Heidelberg, Germany). ProSP-B as a possible biomarker in idiopathic interstitial pneumonias (ILD). Eur Respir J 2012; 40: Suppl. 56, 1767

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006 Non-IPF idiopathic interstitial pneumonia (IIPs) Source: ERS Course 2016 Year: 2016 Clinical-radiographic-pathologic diagnosis in idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002 Idiopathic pulmonary fibrosis - IPF Source: Respipedia Article Year: 2018 Histology and pathogenesis of usual interstitial pneumonia (UIP) versus nonspecific interstitial pneumonia (NSIP): progressive remodeling or resolution and healing? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006 Clinical categorisation of idiopathic interstitial pneumonia Source: Annual Congress 2005 - Idiopathic pulmonary fibrosis: new concepts in its pathogenesis and management Year: 2005 CT features of fibrosing alveolitis in rheumatoid arthritis (FARA): a comparison with idiopathic usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP) Source: Eur Respir J 2003; 22: Suppl. 45, 197s Year: 2003 Fibrosing alveolitis in rheumatoid arthritis (FARA):a survival comparison with idiopathic usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP) Source: Eur Respir J 2003; 22: Suppl. 45, 197s Year: 2003 Histopathological assessment and classification Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias Year: 2006 Clinical significance of histological classification of idiopathic interstitial pneumonia Source: Eur Respir J 2002; 19: 275-283 Year: 2002 The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias Source: Eur Respir Rev 2008; 17: 108-115 Year: 2008 Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia Source: Eur Respir J 2002; 19: 1114-1118 Year: 2002 Interstital lung diseases: update 2005 Source: Annual Congress 2005 - Clinical year in review Year: 2005 Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia Source: International Congress 2017 – Lung function testing Year: 2017 Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias Source: Eur Respir J 2011; 37: 1119-1127 Year: 2011 Non-IPF idiopathic interstitial pneumonias Source: School Course 2014 - Interstitial lung diseases Year: 2014 Interstitial lung disease (ILD) in association with polymyositis-dermatomyositis (PM/DM) with predominant lymphocytic alveolitis and anti-Jo-1-antibodies Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002 Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis Source: Eur Respir J 2001; 18: 43S-55S Year: 2001 Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions Year: 2010